Home/Pipeline/Ecopipam

Ecopipam

Tourette Syndrome

Phase 3 / Pre-NDAActive

Key Facts

Indication

Tourette Syndrome

Phase

Phase 3 / Pre-NDA

Status

Active

Company

Emalex Biosciences

About Emalex Biosciences

Emalex Biosciences is a private, clinical-stage biotech advancing ecopipam, a first-in-class D1 receptor antagonist, for Tourette syndrome. The company's Phase 3 trial met its primary and secondary endpoints, positioning it for a potential NDA submission and addressing a significant unmet need in a patient population with limited treatment options. With an active Expanded Access Program authorized by the FDA, Emalex is nearing a pivotal transition point towards commercialization. The company operates with a focused pipeline and a clear mission to alleviate the burden of tic disorders.

View full company profile

Therapeutic Areas

Tourette Syndrome Central Nervous System Disorders

Other Tourette Syndrome Drugs

Drug	Company	Phase	Status
SCI-110	SciSparc	Phase IIb	Active
SOM3366	SOM Biotech	Preclinical	Active
Valbenazine (INGREZZA)	Neurocrine Biosciences	Phase II	Active (T-Force GOLD)
Sepranolone	Relmada Therapeutics	Phase 2a	Completed